文献速递临床免疫临床生化

NT-IGFBP-4:急性心力衰竭风险预测的新型生物标志物

NT-IGFBP-4: A novel biomarker for risk prediction in acute heart failure.
PubMed 文献 · Clin Chim Acta · 2026-07-08

本研究纳入309例急性心力衰竭患者,采用经验证的化学发光免疫分析法检测基线NT-IGFBP-4与NT-proBNP,随访1年评估心力衰竭再住院和全因死亡。结果显示NT-IGFBP-4对30天结局独立预测(HR=10.07[3.10-32.68],p<0.001),而NT-proBNP失去统计学显著性;两者联合可进一步增强1年风险区分能力。

要点

  • NT-IGFBP-4是急性心衰独立的预后标志物,30天预测优于NT-proBNP
  • NT-IGFBP-4与NT-proBNP联合评估可提升1年风险区分能力
  • NT-IGFBP-4与hs-CRP、hs-cTnI仅呈弱相关

核心结论

  • NT-IGFBP-4是急性心力衰竭的新型独立预后生物标志物,支持其用于多标志物管理策略。

研究设计与样本

  • 纳入309例急性心力衰竭患者,检测基线NT-IGFBP-4(化学发光免疫分析法)和NT-proBNP,随访至1年观察心衰再住院和全因死亡。

主要发现

  • 随访期间81例发生临床事件,包括10例死亡和71例再住院。
  • 30天结局中,相互调整后NT-IGFBP-4独立预测(HR=10.07[3.10-32.68],p<0.001),NT-proBNP无统计学意义(HR=2.68[0.72-10.01],p=0.142)。
  • 1年结局中,NT-IGFBP-4(HR=3.27[1.80-5.91],p<0.001)和NT-proBNP(HR=2.04[1.18-3.53],p=0.010)均为独立预测因子。
  • 两者联合评估进一步改善1年风险区分(HR=5.72[2.73-11.98],p<0.001)。

临床怎么用

  • 在急性心衰患者中可检测NT-IGFBP-4以辅助30天和1年风险分层
  • NT-IGFBP-4与NT-proBNP联合使用可能优化风险预测

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Insulin-like growth factor binding protein-4 (IGFBP-4) fragments generated by PAPP-A-mediated proteolysis are emerging biomarkers of myocardial stress and remodeling. Although elevated N-terminal IGFBP-4 (NT-IGFBP-4) has been associated with heart failure (HF), its prognostic value remains unclear. This study evaluated the prognostic performance of NT-IGFBP-4, measured using a validated chemiluminescent immunoassay, in patients with acute heart failure (AHF) and compared it with the conventional biomarker NT-proBNP. METHODS: A total of 309 patients with AHF were included. Baseline NT-IGFBP-4 and NT-proBNP were measured, and patients were followed for up to 1 year for HF rehospitalization and all-cause mortality. The prognostic performance of each biomarker and their combination for 30-day and 1-year outcomes was evaluated using ROC analysis, Kaplan-Meier analysis, and Cox proportional hazards regression with multivariable adjustment for clinical factors and the other biomarker. Optimal cut-off values were derived from ROC analysis. RESULTS: During follow-up, 81 patients experienced clinical events, including 10 deaths and 71 hospital readmissions. NT-IGFBP-4 showed a moderate correlation with NT-proBNP, but only weak associations with hs-CRP and hs-cTnI. For 30-day outcomes, NT-IGFBP-4 remained independently predictive after mutual adjustment (HR = 10.07[3.10-32.68], p < 0.001), whereas NT-proBNP lost statistical significance under the same conditions (HR = 2.68[0.72-10.01], p = 0.142). For 1-year outcomes, both NT-IGFBP-4 (HR = 3.27[1.80-5.91], p < 0.001) and NT-proBNP (HR = 2.04[1.18-3.53], p = 0.010) remained independent predictors after adjustment for clinical covariates and each other. Notably, the combined assessment of both biomarkers further enhanced 1-year risk discrimination (HR = 5.72[2.73-11.98], p < 0.001). CONCLUSIONS: NT-IGFBP-4 is a novel, independent prognostic biomarker in AHF, supporting its use in multimarker strategies for patient management.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Li L, Wang J, Chen C, et al. NT-IGFBP-4: A novel biomarker for risk prediction in acute heart failure. Clin Chim Acta. 2026. PMID: 42419668. doi:10.1016/j.cca.2026.121229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。